» Articles » PMID: 29876018

Risk Factors for Hemoglobinuria After Ultrasonography-guided Percutaneous Microwave Ablation for Large Hepatic Cavernous Hemangiomas

Overview
Journal Oncotarget
Specialty Oncology
Date 2018 Jun 8
PMID 29876018
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Thermal ablation of large hepatic cavernous hemangiomas may lead to intravascular hemolysis, hemoglobinuria, and even acute renal failure. This study aimed to identify the risk factors associated with hemoglobinuria after ultrasonography-guided percutaneous microwave ablation for large hepatic cavernous hemangiomas. In our study, 11 related risk factors were analyzed using univariate and multivariate binary logistic regression model and Receiver operating characteristic curves to determine the contribution to hemoglobinuria after microwave ablation for 49 patients with 51 hepatic cavernous hemangiomas. By multivariate analysis, the ablation time ( = 0.021; Odds Ratio, 1.005), and the number of antenna insertions ( = 0.036; Odds Ratio, 3.568) were the independent risk factors associated with hemoglobinuria. The cutoff value for ablation time and the number of antenna insertions in predicting the presence of hemoglobinuria was 1185s (sensitivity, 75%; specificity, 69%) and 4.5 (sensitivity, 55%; specificity, 83%), respectively. Less than 5 of antenna insertions and less than 20 mins of ablation time may therefore be recommended in patients with microwave ablation of large hepatic cavernous hemangiomas, in order to reduce the occurrence of hemoglobinuria. This is the first report about the risk factors analysis associated with hemoglobinuria after thermal ablation for large hepatic cavernous hemangiomas.

Citing Articles

Phloretin induces G2/M arrest and apoptosis by suppressing the β-catenin signaling pathway in colorectal carcinoma cells.

Kapoor S, Padwad Y Apoptosis. 2023; 28(5-6):810-829.

PMID: 36884140 DOI: 10.1007/s10495-023-01826-4.


Safety and efficacy of microwave versus radiofrequency ablation for large hepatic hemangioma: a multicenter retrospective study with propensity score matching.

Kong J, Gao R, Wu S, Shi Y, Yin T, Guo S Eur Radiol. 2022; 32(5):3309-3318.

PMID: 35091785 DOI: 10.1007/s00330-021-08425-4.


Complications of Radiofrequency Ablation for Hepatic Hemangioma: A Multicenter Retrospective Analysis on 291 Cases.

Wu S, Gao R, Yin T, Zhu R, Guo S, Xin Z Front Oncol. 2021; 11:706619.

PMID: 34395280 PMC: 8356044. DOI: 10.3389/fonc.2021.706619.


The value of 3D visualization operative planning system in ultrasound-guided percutaneous microwave ablation for large hepatic hemangiomas: a clinical comparative study.

Li X, An C, Liu F, Cheng Z, Han Z, Yu X BMC Cancer. 2019; 19(1):550.

PMID: 31174503 PMC: 6555953. DOI: 10.1186/s12885-019-5682-5.

References
1.
Park S, Tak W, Jung M, Jeon S, Cho C, Kweon Y . Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation. J Hepatol. 2010; 54(3):559-65. DOI: 10.1016/j.jhep.2010.07.024. View

2.
Watzke H, Linkesch W, Hay U . Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal. J Clin Gastroenterol. 1989; 11(3):347-50. DOI: 10.1097/00004836-198906000-00022. View

3.
Heyman S, Rosen S, Fuchs S, EPSTEIN F, Brezis M . Myoglobinuric acute renal failure in the rat: a role for medullary hypoperfusion, hypoxia, and tubular obstruction. J Am Soc Nephrol. 1996; 7(7):1066-74. DOI: 10.1681/ASN.V771066. View

4.
Schnelldorfer T, Ware A, Smoot R, Schleck C, Harmsen W, Nagorney D . Management of giant hemangioma of the liver: resection versus observation. J Am Coll Surg. 2010; 211(6):724-30. DOI: 10.1016/j.jamcollsurg.2010.08.006. View

5.
Wanless I . Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990; 11(5):787-97. DOI: 10.1002/hep.1840110512. View